Lixte Biotechnology

Historical price data

Lixte Biotechnology is a clinical-stage company focused on developing novel small molecule PP2A inhibitors to enhance existing cancer treatments. Its core achievement is the advancement of its lead asset, LB-100, into Phase 1b and Phase 2 trials in combination with chemotherapy and immunotherapy for indications like ovarian clear cell carcinoma and metastatic colon cancer. The company's strategy leverages a lean operational model to generate clinical proof-of-concept data that can attract partnership interest, given the broad potential of its platform to sensitize tumors to standard-of-care regimens. Lixte is publicly traded but operates as a micro-cap entity, reflecting its early-stage, high-risk/high-reward profile.

A proprietary platform based on the inhibition of Protein Phosphatase 2A (PP2A) using first-in-class small molecules, primarily LB-100, designed to enhance the efficacy of chemotherapy and immunotherapy by overcoming tumor resistance mechanisms.

Lixte holds a first-in-class position with no direct clinical competitors targeting PP2A inhibition as a treatment enhancer. Broader competition includes numerous companies developing chemosensitizers and immunotherapy combination agents through different mechanisms. The primary near-term challenge is validating its unique approach against established combinatorial strategies.